Interleukin-2 given to asymptomatic HIV-infected individuals leads to an exaggerated response of the pituitary gland to the action of CRH

Clinical Endocrinology

Volumn 59, Issue 1, 2003, Pages 104-109

  Witzke, Oliver ^a   Winterhagen, Toni ^a   Kribben, Andreas ^a   Philipp, Thomas ^a   Mann, Klaus ^a   Reinhardt, Walter ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; DIDANOSINE; HYDROCORTISONE; INDINAVIR; LAMIVUDINE; PROTEINASE INHIBITOR; RECOMBINANT INTERLEUKIN 2; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; DRUG ACTIVITY; DRUG MECHANISM; DRUG RESPONSE; FEVER; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROCORTISONE BLOOD LEVEL; HYPOPHYSIS; MALAISE; MALE; PRIORITY JOURNAL; STIMULATION; SYMPTOMATOLOGY;

ADRENOCORTICOTROPIC HORMONE; ADULT; ANALYSIS OF VARIANCE; ANTI-HIV AGENTS; CORTICOTROPIN-RELEASING HORMONE; HIV INFECTIONS; HUMANS; HYDROCORTISONE; INTERLEUKIN-2; MALE; MIDDLE AGED; PITUITARY GLAND; PROSPECTIVE STUDIES; STIMULATION, CHEMICAL;

EID: 0038772415     PISSN: 03000664     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2265.2003.01803.x     Document Type: Article

References (15)

1. Chun, T.W., Engel, D., Mizell, S.B., Hallahan, C.W., Fischette, M., Davey, R.T., Dybul, M., Kovacs, J.A., Metcalf, J.A., Mican, J.M., Berrey, M.M., Corey, L., Lane, H.C. & Fauci, A.S. (1999) Effect of interleukin-2 on the pool of latently infected, resting CD4 T cells in HIV-1 infected patients receiving highly acitve anti-retroviral therapy. Nat Med, 5, 651-655.
2. Denicoff, K.D., Durkin, T.M., Lotze, M.T., Quinlan, P.E., Davis, C.L., Listwak, S.J., Rosenberg, S.A. & Rubinow, D.R. (1989) The neuroendocrine effects of interleukin-2 treatment. Journal of Clinical Endocrinology and Metabolism, 69, 402-410.
3. Hanisch, U.K., Rowe, W., Sharma, S., Meaney, M.J. & Quirion, R. (1994) Hypothalamic-pituitary-adrenal activity during chronic central administration of interleukin-2. Endocrinology, 135, 2465-2472.
4. Karanth, S., Lyson, K. & McCann, S.M. (1993) Role of nitric oxide in interleukin 2-induced corticotropin-releasing factor release from incubated hypothalami. Proceedings of the National Academy of Sciences of the USA, 90, 3383-3387.
5. Karanth, S., Lyson, K. & McCann, S.M. (1994) Cyclosporin A inhibits interleukin-2-induced release of corticotropin-releasing hormone. Neuroimmunomodulation, 1, 82-85.
6. Karanth, S., Lyson, K. & McCann, S.M. (1999) Effects of cholinergic agonists and antagonists on interleukin-2-induced corticotropin-releasing hormone release from the mediobasal hypothalamus. Neuroimmunomodulation, 6, 168-174.
7. Kovacs, J.A., Baseler, M., Dewar, R.J., Vogel, S., Davey, R.T., Falloon, J., Polis, M.A., Walker, R.E., Stevens, R. & Salzmann, N.P. (1995) Increases in CD4-T-lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. New England Journal of Medicine, 332, 567-575.
8. Levy, Y., Capitant, C., Houhou, S., Carriere, I., Viard, J.P., Goujard, C., Gastaut, J.A., Oksenhendler, E., Boumsell, L., Gomard, E., Rabian, C., Weiss, L., Guillet, J.G., Delfraissy, J.F., Aboulker, J.P. & Seligmann, M. (1999) Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomised controlled trial. ANRS 048 study group. Lancet, 353, 1923-1929.
9. Lotze, M.T., Matory, Y.L., Ettinghausen, S.E., Rayner, A.A., Sharrow, S.O., Seipp, C.A., Custer, M.C. & Rosenberg, S.A. (1985) In vivo administration of purified human interleukin II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL. Journal of Immunology, 135, 2865-2875.
10. McCann, S.M., Kimura, M., Karanth, S., Yu, W.H., Mastronardi, C.A. & Rettori, V. (2000) The mechanisms of action of cytokines to control the release of hypothalamic and pituitary hormones in infection. Annals of New York Academy of Science, 917, 4-18.
11. Mastorakis, G., Chrousos, G.P. & Weber, J.S. (1993) Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. Journal of Clinical Endocrinology and Metabolism, 77, 1690-1694.
12. Raab, C., Weidmann, E., Schmidt, A., Bergmann, L., Badenhoop, K., Usadel, K.H. & Haak, T. (1999) The effects of interleukin-2 treatment on endothelin and the activation of the hypothalamic-pituitary-adrenal axis. Clinical Endocrinology, 50, 37-44.
13. Witzke, O., Winterhagen, T., Reinhardt, W., Heemann, U., Grosse-Wilde, H., Kreuzfelder, E., Roggendorf, M. & Philipp, T.H. (1998) Comparison between subcutaneous and intravenous interleukin-2 treatment in HIV disease. Journal of Internal Medicine, 244, 235-240.
14. Witzke, O., Winterhagen, T., Saller, B., Roggenbuck, U., Lehr, I., Philipp, T.H., Mann, K. & Reinhardt, W. (2001) Transient stimulatory effects on the pituitary-thyroid axis in patients treated with interleukin-2. Thyroid, 11, 665-670.
15. Yanovski, J.A., Miller, K.D., Kino, T., Friedman, T.C., Chrousos, G.P., Tsigos, C. & Falloon, J. (1999) Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy. Journal of Clinical Endocrinology and Metabolism, 84, 1925-1931.